Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is N/A as of 2026-10-06T15:37:51.988Z.
Calculation as of: 2026-10-06T15:37:51.988Z.
Quote observation: 2026-10-06T15:35:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
N/A
Market Cap
$14.09M
PB Ratio
0.86
TTM Avg
1.08
3Y Avg
1.08
5Y Avg
1.08
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Obsidian Therapeutics Inc. (OBX) | $14.29M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.04M | 0.21 | 0.22 | 3.10 | 11.65 |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.09M | 0.86 | 1.08 | 1.08 | 1.08 |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | 2.31 | 1.80 | 2.33 | 1.81 |
| IN8bio, Inc. (INAB)vs › | $13.81M | 0.75 | 0.85 | 1.26 | 1.45 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.06M | N/A | 11.36 | 9.73 | 6.96 |
| Optimi Health Corp. (OPTH)vs › | $13.44M | 1.08 | 5.06 | 17.14 | 12.69 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.03M | 0.30 | 0.27 | 0.24 | 0.34 |
| Cytosorbents Corporation (CTSO)vs › | $13.01M | N/A | 6.78 | 4.59 | 3.93 |
| Passage Bio, Inc. (PASG)vs › | $13.27M | 2.98 | 1.49 | 0.82 | 0.68 |
P/B Ratio
N/A
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
